Mirum Pharmaceuticals, Inc. MIRM Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$798.84M-933% | -$23.36M+73.4% | -$41.42M+58.5% | -$58.56M+46.4% | -$77.34M+51.2% | ||
| $25.07M+4.4% | $24.24M+2.6% | $24.23M+5.0% | $24.22M+23.1% | $24.02M+58.5% | ||
| $91.82M+73.9% | $71.42M+47.4% | $65.65M+46.2% | $59.43M+43.6% | $52.8M+39.3% | ||
| $1.76M+4.8% | $1.74M+4.7% | $1.72M+4.6% | $1.7M+4.2% | $1.68M+9.7% | ||
| $44.11M+7.0% | $48.06M+321% | $39.91M+92.8% | $44.87M+78.7% | $41.23M+35.9% | ||
| $7.7M+57.9% | $8.45M+167% | $6.38M— | $6.12M— | $4.87M— | ||
| —— | —— | —— | —— | —— | ||
| $1.32M-7.6% | $1.4M+76.2% | $1.39M+206% | $1.49M+538% | $1.43M+131% | ||
| -$2.07M-125% | -$1.9M-142% | -$1.6M-100% | -$1.12M-17.1% | -$921K+7.0% | ||
| -$170.98M— | $55.83M— | —— | —— | —— | ||
| $1.58M+54.5% | $954K-3.9% | $374K— | $368K— | $1.02M— | ||
| $98.7M-19.5% | $97.43M+9.4% | $97.41M— | $92.15M— | $122.55M— | ||
| $90.88M+143% | $74.43M+274% | $73.46M+583% | $62.39M+89.1% | $37.33M-57.8% | ||
| $10M-50.0% | $0-100% | $0-100% | $10M— | $20M— | ||
| -$20.4M+80.9% | -$24.96M+72.5% | -$24.96M+73.1% | -$40.77M+84.2% | -$106.89M+20.4% | ||
| $3.77M-40.7% | $0— | $31.14M— | $15.05M— | $6.36M— | ||
| $303.86M+1,230% | $40.14M+127% | $36.48M+158% | $24.25M-88.8% | $22.85M-93.0% | ||
| —— | —— | $2.25M— | $1.99M— | -$355K— | ||
| $114.39M+226% | $75.24M+219% | $59.11M— | -$4.89M— | -$90.6M— | ||
| $2.22M+116% | $2.16M+115% | $2.38M+166% | $2.31M+398% | $1.03M+289% | ||
| $1.76M+4.8% | $1.74M+4.7% | $1.72M+4.6% | $1.7M+4.2% | $1.68M+9.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $2.06M+211% | $419K-22.4% | $207K+47.9% | ||
| $95.61M+134% | $50.1M+24.3% | $56M+28.7% | $44.41M+8.2% | $40.77M-5.8% | ||
| —— | —— | —— | —— | —— | ||
| -$2.07M-125% | -$1.9M-142% | -$1.6M-100% | -$1.12M-17.1% | -$921K+7.0% | ||
| $10.37M+548% | $5.66M+278% | $4.03M+84.2% | $2.75M— | $1.6M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$4.73M+50.2% | ||
| $1.89M+25.4% | $1.73M+27.8% | $1.64M+45.4% | $1.6M+74.3% | $1.51M— | ||
| $1.32M-7.6% | $1.4M+76.2% | $1.39M+206% | $1.49M+538% | $1.43M+131% | ||
| $10M-50.0% | $0-100% | $0-100% | $10M— | $20M— | ||
| $90.88M+143% | $74.43M+274% | $73.46M+583% | $62.39M+89.1% | $37.33M-57.8% | ||
| —— | —— | —— | —— | —— | ||
| $43.91M+92.2% | $40.14M+127% | $36.48M+150% | $24.25M+56.7% | $22.85M+122% | ||
| $18K+200% | $24K— | $17K— | $9K— | $6K— | ||
| —— | —— | $2.25M— | $1.99M— | -$355K— | ||
| -$2.07M-125% | -$1.9M-142% | -$1.6M-100% | -$1.12M-17.1% | -$921K+7.0% | ||
| $2.82M+79.7% | $2.59M+103% | $2.3M+102% | $1.82M+57.6% | $1.57M+41.8% | ||
| —— | —— | —— | —— | —— | ||
| $6.92M— | $2.44M— | —— | —— | —— | ||
| $649K-42.1% | $688K-38.7% | $756K-34.4% | $730K-36.0% | $1.12M+28.9% | ||
| —— | —— | —— | —— | —— | ||
| $2.22M+116% | $2.16M+115% | $2.38M+166% | $2.31M+398% | $1.03M+289% | ||
| -$172.55M— | $54.87M— | —— | —— | —— | ||
| -$172.55M— | $54.87M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Mirum Pharmaceuticals, Inc. generate?
- Mirum Pharmaceuticals, Inc. (MIRM) generated -$171.0M in operating cash flow over the trailing twelve months.
- What is Mirum Pharmaceuticals, Inc.'s free cash flow?
- After $1.6M of capital expenditures, Mirum Pharmaceuticals, Inc.'s free cash flow was -$172.6M over the trailing twelve months, down 45270.7% year over year.
- Where does Mirum Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
